Company Overview - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (石药创新), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [4] Business Development - In 2024, the company acquired control of Giant Bio, expanding its main business into the biopharmaceutical sector, marking a key step in its strategic transformation [5] - The company is developing innovative therapies targeting unmet clinical needs in significant disease areas such as tumors, autoimmune diseases, and infectious diseases [5] - The company has a strong pipeline with 15 drugs in clinical or late-stage development, including 9 ADC drugs and 1 mRNA vaccine [5] Financial Performance - The company's revenue for the fiscal years 2022, 2023, 2024, and the seven months ending July 31, 2025, were approximately RMB 2.838 billion, RMB 2.539 billion, RMB 1.980 billion, and RMB 1.241 billion respectively [9] - The company's profit for the same periods was approximately RMB 294 million, RMB 126 million, a loss of RMB 304 million, and a loss of RMB 226 million respectively [10] - The gross profit margin for the fiscal years 2022, 2023, 2024, and the seven months ending July 31, 2025, were approximately 46.8%, 45.6%, 41.8%, and 38.3% respectively [11] Industry Outlook - The global pharmaceutical market is expected to grow from USD 1,324.5 billion in 2019 to USD 1,542 billion in 2024, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030 [13] - The global oncology drug market is projected to grow from USD 143.5 billion in 2019 to USD 253.3 billion in 2024, with a CAGR of 12.0% [14] - The global antibody drug market is expected to expand from USD 163.8 billion in 2019 to USD 254.3 billion in 2024, with a CAGR of 9.2% [15]

Company Overview - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [4] Business Development - In 2024, the company acquired control of Giant Bio, expanding its main business into the biopharmaceutical sector, marking a key step in its strategic transformation [5] - The company is engaged in the development of innovative therapies targeting unmet clinical needs in significant disease areas such as tumors, autoimmune diseases, and infectious diseases [5] - The company has a strong technical foundation in antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with plans to commercialize two antibody drugs in the second half of 2024 [5] Product Pipeline - As of December 1, 2025, the company has 15 drugs in clinical or late-stage development, including 9 ADCs and 1 mRNA vaccine [5] - The company’s mRNA vaccine products, including the first domestically developed COVID-19 mRNA vaccine, have been included for emergency use in China [5] Financial Performance - The company's revenue for the fiscal years ending July 31 for 2022, 2023, 2024, and the first seven months of 2025 were approximately RMB 2.838 billion, RMB 2.539 billion, RMB 1.980 billion, and RMB 1.241 billion respectively [8] - The company's profit for the same periods was approximately RMB 294 million, RMB 126 million, a loss of RMB 304 million, and a loss of RMB 226 million respectively [8] - The gross profit margin for these years was approximately 46.8%, 45.6%, 41.8%, and 38.3% [9] Industry Outlook - The global pharmaceutical market is expected to grow from USD 1,324.5 billion in 2019 to USD 1,542 billion in 2024, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030 [11] - The Chinese pharmaceutical market is projected to grow from RMB 1,629.7 billion in 2024 to RMB 2,129.7 billion in 2030, with a CAGR of 4.6% from 2024 to 2030 [11] - The global oncology drug market is expected to expand from USD 143.5 billion in 2019 to USD 253.3 billion in 2024, with a CAGR of 12.0% [12] Market Position - The company is positioned as a significant player in the biopharmaceutical sector, focusing on innovative therapies and addressing unmet clinical needs [5][11] - The company has established a solid partnership with leading beverage companies, leveraging its expertise in caffeine production and health food products [6]

Core Viewpoint - The company, Shiyao Innovation Pharmaceutical Co., Ltd. (stock code: 300765.SZ), has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor. The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1]. Group 1: Company Overview - Shiyao Innovation has maintained its position as the world's largest producer of synthetic caffeine by revenue and shipment volume from 2020 to 2024, according to Frost & Sullivan [1]. - Since its establishment in 2006, the company has concentrated on the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [1]. Group 2: Market Presence - As of the latest feasible date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [1]. - The company has established solid partnerships with leading international beverage industry clients, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [1].

Group 1 - The company, Shiyao Innovation Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1] - According to Frost & Sullivan, the company has maintained its position as the world's largest producer of synthetic caffeine by revenue and volume from 2020 to 2024 [1][5] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [5] - As of the last practicable date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [5] - The company has established solid partnerships with leading international beverage companies, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [5]

据港交所12月10日披露，石药创新制药股份有限公司(简称：石药创新，300765.SZ)向港交所主板递交 上市申请，中信证券为其独家保荐人。据招股书，该公司专注于生物制药、功能性原料及保健食品的研 发、生产与商业化。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司始终 保持着全球最大化学合成咖啡因生产商地位。 | [編纂]項下的[編纂]數目 | : [编纂]股H股(視乎[編纂]) | | --- | --- | | [編纂]數目 | :「編纂]股H股(可予[編纂]) | | [編纂]數目 | : [編纂]股H股(可予[編纂]及[編纂]) | | 最高[編纂] | : 每股H股[編纂]港元,另加[編纂] | | | (「編纂]港元,多繳款項可予退還) | | 面值 | 每股H股人民幣1.00元 | | [編纂] | : [編纂] | 自2006年成立以来，该公司始终专注于高质量咖啡因的研发与生产。该公司主要生产用作功能性饮料中 的食品添加剂的咖啡因。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司 始终保持着全球最大化学合成咖啡因生产商地位。截至最后实际可 ...

Group 1 - The company, Shiyao Innovation Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [1] - According to Frost & Sullivan, the company has maintained its position as the world's largest producer of synthetic caffeine by revenue and volume from 2020 to 2024 [1][5] Group 2 - Since its establishment in 2006, the company has specialized in the research and production of high-quality caffeine, primarily used as a food additive in functional beverages [5] - As of the last feasible date (December 1, 2025), the company's products have been sold in 65 countries and regions globally, with North America and Europe being its main markets [5] - The company has established solid partnerships with leading international beverage companies, including Coca-Cola (since 2006), PepsiCo (since 2007), and Red Bull GmbH (since 2008), serving as their global caffeine supplier [5]

Core Insights - The Tianhong Food and Beverage ETF (159736) has seen significant trading activity, with a transaction volume of 27.0065 million yuan and a net inflow of 15.2008 million yuan as of December 9, indicating strong investor interest in the sector [1][2]. Group 1: ETF Performance - The Tianhong Food and Beverage ETF (159736) tracked the CSI Food and Beverage Index (930653), which rose by 0.42% [1]. - Notable constituent stocks include Huanlejia (300997) with a 12.83% increase, XinNuoWei (300765) up by 9.28%, and Huaiqi Mountain (601579) rising by 3.91% [1]. - Over the past five trading days, the ETF has attracted a total of 13.7841 million yuan in net inflows [1]. Group 2: Product Highlights - The Tianhong Food and Beverage ETF (159736) primarily invests in high-end and mid-range liquor stocks, with approximately 60% of its portfolio allocated to leading liquor brands and 40% to beverages, dairy, and seasoning sectors [3]. - The top ten weighted stocks in the ETF include major brands such as Moutai, Wuliangye, and Yanghe, as well as dairy giant Yili and seasoning leader Haitian [3]. Group 3: Market Events - The Guizhou Provincial Government has proposed measures to boost liquor sales, including enhancing online promotions and creating diverse consumption scenarios [6]. - The measures aim to increase the market presence of Guizhou liquor through initiatives like issuing consumption vouchers and supporting financial collaborations with liquor companies [6]. Group 4: Agricultural Sector Insights - The Tianhong Agricultural ETF (512620) has also shown positive performance, with the CSI Agricultural Theme Index (000949) increasing by 0.49% [2]. - Key stocks in the agricultural ETF include Luoniushan (000735) with a 7.76% rise and Shengnong Development (002299) up by 3.59% [2]. - The agricultural sector is currently experiencing a decrease in pork prices, with the national average price at a five-year low, indicating a potential shift in market dynamics [7]. Group 5: Institutional Perspectives - Dongwu Securities has expressed a cautiously optimistic outlook for consumer spending, suggesting that while consumption has been under pressure, there are signs of marginal improvement expected by 2026 [8]. - The report highlights the importance of recent government policies aimed at stimulating consumption, including subsidies for various sectors [8].

Core Viewpoint - The food and beverage sector experienced a rise against the market trend, with the Food ETF (515710) showing a recovery after a brief dip, indicating potential investment opportunities in this sector [1][7]. Group 1: Market Performance - The Food ETF (515710) opened lower but quickly rebounded, achieving a maximum intraday increase of 0.68% and closing up by 0.34% [1][7]. - Key stocks in the sector, particularly in the liquor category, saw significant gains, with New Noble rising over 9%, Yanjing Beer increasing by over 3%, and several others like Jiu Gui Jiu and Jin Zhong Zi Jiu rising over 2% [1][7]. Group 2: Policy Impact - On December 9, a draft policy from Guizhou Province aimed at promoting liquor sales was released, focusing on enhancing online sales and expanding market reach through various channels, including supermarkets and convenience stores [3][9]. - This policy is expected to directly benefit Guizhou liquor companies by creating new sales opportunities and stabilizing market expectations [3][9]. Group 3: Valuation Insights - The food and beverage sector is currently at a historical low in terms of valuation, with the Food ETF's underlying index PE ratio at 19.93, placing it in the 4.11% percentile of the last decade, suggesting a favorable long-term investment opportunity [3][9]. - Analysts recommend focusing on companies with strong demand stability and risk resilience, as well as those actively exploring new products and sales channels [10]. Group 4: Investment Recommendations - It is suggested to consider the Food ETF (515710) for exposure to core assets in the food and beverage sector, which includes a significant allocation to leading high-end and mid-range liquor stocks [10]. - The ETF also diversifies into beverage, dairy, seasoning, and beer sectors, with top holdings including renowned brands like Moutai and Yili [10].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 本文件為草擬本，其所載資訊不完整及可作更改。閱讀本文件有關資料時，必須一併細閱本文件首頁「警告」一節。 CSPC Innovation Pharmaceutical Co., Ltd. 石藥創新製藥股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、其獨家保薦人、保薦人兼整體協調人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處長登記的本 公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.47% on December 9, with the Shanghai Composite Index closing at 3909.52, down 0.37%, and the Shenzhen Component Index at 13277.36, down 0.39% [1] Stock Performance - The leading stock decline was observed in "退市苏吴," which fell by 67.74% to a closing price of 0.40, with a trading volume of 2.0568 million shares and a transaction value of 90.8383 million yuan [1] - Other notable declines included "康艺药业" down 7.85% to 10.80, "母南通的" down 7.67% to 7.82, and "广济药业" down 5.85% to 7.89 [1] Capital Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 6.92 billion yuan from institutional investors, while retail investors contributed a net inflow of 3.85 billion yuan [3] - Specific stocks like "恒瑞医药" had a net inflow of 1.37 billion yuan from institutional investors, while "退市苏吴" saw a net inflow of 383.935 million yuan [3]